Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Kyndryl Holdings Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.18 (market cap $12.58B), while Kyndryl Holdings Inc trades at $11.77 (market cap $2.59B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 4.9× Kyndryl Holdings Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Kyndryl Holdings Inc for 36 Days on average.
| HALO | KD | |
|---|---|---|
Market Cap | $12.58B | $2.59B |
Volume | 2,179,278 | 5,354,348 |
Sector | Health | Technology |
52-Week High | $115.22 | $29.76 |
52-Week Low | $61.63 | $10.59 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $14.49B | $5.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kyndryl (KD) trades at $11.45, down 0.26% on the day, reflecting a challenging technical and fundamental environment. The stock exhibits a bearish technical signal with key support at $11 and resistance at $12, while recent earnings misses in Q4 2025 and Q1 2026 contrast with a beat in Q2 2026. Despite a low P/S ratio of 0.18 and positive net income of $252 million in 2025, the company's revenue has declined from $18.3B in 2022 to $15.1B in 2025. Recent news highlights a strategic focus on AI, including the launch of an innovation lab and the acquisition of Healthcare IT Leaders.
The outlook for KD is mixed, with a consensus price target of $14.67 suggesting potential upside, but analyst sentiment is cautious with 71% hold ratings. Key opportunities include AI-driven growth and improving profitability, while risks involve persistent revenue declines, high debt levels, and competitive pressures in the IT services sector. Execution on AI initiatives and future earnings performance will be critical for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
